Arcus Biosciences, Inc.
RCUS · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $150 | $127 | $206 | $148 |
| Short-Term Investments | $828 | $632 | $803 | $351 |
| Receivables | $25 | $42 | $43 | $747 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $13 | $30 | $14 | $16 |
| Total Curr. Assets | $1,016 | $831 | $1,066 | $1,262 |
| Property Plant & Equip (Net) | $47 | $51 | $135 | $137 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $14 | $107 | $134 | $185 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $73 | $106 | $10 | $8 |
| Total NC Assets | $134 | $264 | $279 | $330 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $1,150 | $1,095 | $1,345 | $1,592 |
| Liabilities | – | – | – | – |
| Payables | $18 | $17 | $20 | $10 |
| Short-Term Debt | $12 | $11 | $3 | $5 |
| Tax Payable | $1 | $0 | $0 | $2 |
| Deferred Revenue | $85 | $91 | $97 | $102 |
| Other Curr. Liab. | $110 | $65 | $73 | $47 |
| Total Curr. Liab. | $226 | $184 | $193 | $166 |
| LT Debt | $48 | $0 | $117 | $117 |
| Deferred Rev, NC | $234 | $307 | $355 | $462 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $157 | $142 | $23 | $5 |
| Total NC Liab. | $439 | $449 | $495 | $584 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $12 | $11 | $117 | $117 |
| Total Liabilities | $665 | $633 | $688 | $750 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $1,617 | $1,311 | $1,206 | $0 |
| Retained Earnings | -$1,132 | -$849 | -$542 | -$275 |
| AOCI | $0 | $0 | -$7 | -$1 |
| Other Equity | $0 | $0 | $0 | $1,118 |
| Total Equity | $485 | $462 | $657 | $841 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $1,150 | $1,095 | $1,345 | $1,592 |
| Net Debt | -$90 | -$116 | -$86 | -$26 |